Evidence map›Paper›PMID 39341862›Full record

ArticleScientific reports2024

Identification of candidate causal variants and target genes at 41 breast cancer risk loci through differential allelic expression analysis.

Joana M Xavier, Ramiro Magno, Roslin Russell, Bernardo P de Almeida, Ana Jacinta-Fernandes, André Besouro-Duarte, Mark Dunning, Shamith Samarajiwa, Martin O'Reilly, António M Maia and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Joana M XavierCintesis@Rise, Universidade do Algarve, Faro, Portugal. jgxavier@ualg.pt.
Ramiro MagnoCintesis@Rise, Universidade do Algarve, Faro, Portugal.
Roslin RussellCambridge Institute - CRUK, University of Cambridge, Cambridge, UK.
Bernardo P de AlmeidaFaculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve, Faro, Portugal.
Ana Jacinta-FernandesFaculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve, Faro, Portugal.
André Besouro-DuarteCintesis@Rise, Universidade do Algarve, Faro, Portugal.
Mark DunningCambridge Institute - CRUK, University of Cambridge, Cambridge, UK.
Shamith SamarajiwaMedical Research Council (MRC) Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK.
Martin O'ReillyCambridge Institute - CRUK, University of Cambridge, Cambridge, UK.
António M MaiaCintesis@Rise, Universidade do Algarve, Faro, Portugal.
Cátia L RochaFaculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve, Faro, Portugal.
Nordiana RosliFaculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve, Faro, Portugal.
Bruce A J PonderCambridge Institute - CRUK, University of Cambridge, Cambridge, UK.
Ana-Teresa MaiaCintesis@Rise, Universidade do Algarve, Faro, Portugal. atmaia@ualg.pt.

Funding

FP7 People: Marie-Curie Actions FP7/2007-2013/under REA grant agreement no. 303745Fundação para a Ciência e a Tecnologia DL 57/2016/CP1361/CT0042Fundação para a Ciência e a Tecnologia POCI "01-0145-" EDER-022184 "GenomePT"Fundação para a Ciência e a Tecnologia RISE - LA/P/0053/2020
6 · The paper itself

Abstract

Understanding breast cancer genetic risk relies on identifying causal variants and candidate target genes in risk loci identified by genome-wide association studies (GWAS), which remains challenging. Since most loci fall in active gene regulatory regions, we developed a novel approach facilitated by pinpointing the variants with greater regulatory potential in the disease's tissue of origin. Through genome-wide differential allelic expression (DAE) analysis, using microarray data from 64 normal breast tissue samples, we mapped the variants associated with DAE (daeQTLs). Then, we intersected these with GWAS data to reveal candidate risk regulatory variants and analysed their cis-acting regulatory potential. Finally, we validated our approach by extensive functional analysis of the 5q14.1 breast cancer risk locus. We observed widespread gene expression regulation by cis-acting variants in breast tissue, with 65% of coding and noncoding expressed genes displaying DAE (daeGenes). We identified over 54 K daeQTLs for 6761 (26%) daeGenes, including 385 daeGenes harbouring variants previously associated with BC risk. We found 1431 daeQTLs mapped to 93 different loci in strong linkage disequilibrium with risk-associated variants (risk-daeQTLs), suggesting a link between risk-causing variants and cis-regulation. There were 122 risk-daeQTL with stronger cis-acting potential in active regulatory regions with protein binding evidence. These variants mapped to 41 risk loci, of which 29 had no previous report of target genes and were candidates for regulating the expression levels of 65 genes. As validation, we identified and functionally characterised five candidate causal variants at the 5q14.1 risk locus targeting the ATG10 and ATP6AP1L genes, likely acting via modulation of alternative transcription and transcription factor binding. Our study demonstrates the power of DAE analysis and daeQTL mapping to identify causal regulatory variants and target genes at breast cancer risk loci, including those with complex regulatory landscapes. It additionally provides a genome-wide resource of variants associated with DAE for future functional studies.

Indexed as

AllelesBreast NeoplasmsGenetic Predisposition to DiseaseGenome-Wide Association StudyPolymorphism, Single NucleotideQuantitative Trait LociFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansBreast cancerCancer predispositionCis-regulationPolymorphism

Identifiers

PMID39341862
PMCPMC11438911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.